Sangamo Therapeutics (SGMOQ) Total Liabilities (2010 - 2025)

Sangamo Therapeutics has reported Total Liabilities for 16 years, with the latest figure at $74.0 million in Q4 2025.

• On a quarterly basis, Total Liabilities fell 6.15% year-over-year to $74.0 million in Q4 2025; TTM through Dec 2025 was $74.0 million, a 6.15% decrease from a year earlier, with the FY2025 full-year figure at $74.0 million, down 6.15% from the prior year.
• Total Liabilities was $74.0 million for Q4 2025 at Sangamo Therapeutics, down from $82.4 million in the prior quarter.
• The five-year high for Total Liabilities was $407.7 million in Q1 2021, with the low at $69.3 million in Q2 2024.
• Average Total Liabilities over 5 years is $182.7 million, with a median of $88.1 million recorded in 2023.
• The sharpest annual moves came in 2021 and 2023: Total Liabilities jumped 114.72% in 2021, then sank 70.23% in 2023.
• Over 5 years, Total Liabilities stood at $346.6 million in 2021, then retreated by 22.8% to $267.6 million in 2022, then slumped by 69.19% to $82.4 million in 2023, then fell by 4.33% to $78.9 million in 2024, then dropped by 6.15% to $74.0 million in 2025.
• The last three Total Liabilities figures came in at $74.0 million (Q4 2025), $82.4 million (Q3 2025), and $78.0 million (Q2 2025), per Business Quant data.